PathGroup Pathologist Co-Authors Molecular Pathology Publication

Dr. Pranil K. Chandra, Assistant Vice President and Medical Director of Molecular Pathology and Genomic Medicine Services at PathGroup, has co-authored a publication titled “The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer: A Report of the Association for Molecular Pathology”.

The Association of Molecular Pathology (AMP) report addresses the challenges in defining the clinical utility of molecular diagnostics for inherited disease and cancer, including molecular diagnostic procedures used for diagnosis, prognosis, risk assessment, prediction of future disease, and monitoring and selection of therapies of disease in patients.  The report puts forth clinical utility definitions that appropriately recognize the contribution and value of molecular diagnostic testing to improve patient care.

The report has been released online ahead of publication in the September 2016 issue of The Journal of Molecular Diagnostics.  Click Here to read the full manuscript.

PathGroup Announces Partnership with digiChart

Includes New Enhanced Lab Interface Exclusively for PathGroup and digiChart Clients

BRENTWOOD, TENN. – (April 8, 2016) – PathGroup, one of the largest private providers of pathology services in the United States, announced today a unique partnership with digiChart, one of the largest specialty-focused EHR providers in the women’s health space.

PathGroup and digiChart have partnered to develop a new ordering interface that will give the digiChart EHR product full bi-directional lab interface capabilities. PathGroup and digiChart clients will be able to both place orders and receive results through their existing digiChart EHR, creating a seamless process that will both save time in the office and simplify the lab ordering workflow for their practice. “PathGroup is committed to providing our clients with superior service. We have always been a leader in utilizing technology to deliver fast, accurate results and this partnership with digiChart adds ease of ordering for our mutual clients to that equation,” stated Dan Valenti, Senior Vice President and Chief Information Officer at PathGroup.

“As one of the largest providers of women’s health services in the United States, PathGroup wanted an EHR partner that showed that same commitment to women’s health providers. We felt that by working together, PathGroup and digiChart could significantly enhance and simplify the workflow for our mutual clients, helping them ultimately better serve their patients,” stated Richard Halstead, Executive Vice President and Chief Commercial Officer at PathGroup.

Built by OB/GYNs for OB/GYNs, digiChart’s specialty-focused EHR mimics the workflow in the OB/GYN practice, improves clinical decision-making, and provides unique functionality to enhance patient care. “This partnership with PathGroup significantly enhances our lab interface capabilities, allowing our clients’ offices to quickly and easily order and receive results for all their lab testing needs, directly in their digiChart EHR,” stated Rodney Hamilton, M.D., Chief Executive Officer at digiChart. digiChart also provides revenue cycle management tools that integrate seamlessly with the EHR, providing faster, more accurate processing of claims.

PathGroup and digiChart look forward to further enhancing the partnership with future collaborations, focused on ensuring clients have services that benefit both their practice and their patients.

About PathGroup

Founded in 1965, PathGroup has evolved into a premier provider of anatomic, clinical and molecular pathology services, as well as one of the largest providers of Women’s Health services in the United States. Privately held and physician centric, PathGroup works seamlessly with customers to provide superior diagnostic services – a vital link in the cycle of patient relationships.  PathGroup uses the latest in proprietary and industry standard technology to deliver fast, accurate results.  The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers and most importantly, patients. One Lab; Total Service.  For more information, visit www.pathgroup.com.

About digiChart

digiChart offers specialized tools, services, and education to help OB/GYN practices compete with the larger practices or hospitals seeking to control more of the care continuum.  Our tools deliver value clinically, operationally, and financially providing insight to know how to make the right changes to keep your practice on course. digiChart has expanded its offering to enhance the foundational EHR with new medical billing services and practice analytics to give OB/GYN practices the resources needed to succeed. Improving the Practice of Women’s Health. For more information, visit digiChart.com.

Contact:

Brent Sower
AVP Marketing
PathGroup
615.234.3908
bsower@pathgroup.com

Kathy Gill
VP Marketing and Communications
digiChart, Inc.
615.481.6646
kgill@digichart.com

PathGroup Launches New SmartGenomics™ Cancer-Specific Testing

Provides Newly Diagnosed Patients Genomic Baseline

BRENTWOOD, TENN. – (June 18, 2015) PathGroup, one of the largest private providers of pathology services in the United States, announced today the launch of new cancer-specific SmartGenomics™ testing, expanding their genomic profiling menu for community-based oncologists. The addition of five diagnostic panels targeting cancers of lung, colon, brain, thyroid and melanoma/GIST represent testing options for newly diagnosed patients, the result of which will enable physicians to make more precise therapeutic recommendations and clinical management decisions.

PathGroup SmartGenomics uses multiple technologies to provide a complete genomic picture of a patient’s individual cancer. Each panel offers cost-effective, tailored genomic testing for its respective disease utilizing guideline recommendations from the National Comprehensive Cancer Network (NCCN). Standard of care diagnostic features include expanded RAS testing in colorectal cancer, biomarkers EGFR, ALK, ROS1, RET, MET in lung cancer, and BRAF, KIT mutation testing in melanoma.

“Genes that are relevant at diagnosis of lung cancer are not the same as those of melanoma or colon adenocarcinoma,” said Pranil K. Chandra, DO, Medical Director of Molecular Pathology Services at PathGroup. “PathGroup has profiled thousands of patients and we have found that the addition of diagnostic testing at biopsy via SmartGenomics and gold-standard technologies are true advances to our customers and ultimately our patients. As evidenced by the plethora of new and upcoming genomically-driven clinical trials, integrating genomic profiling into patient management and therapy selection is the future of clinical oncology practice and cancer pharmacotherapeutic development.”

Results from PathGroup’s cancer-specific panels provide treating clinicians with actionable information, linking the findings to available clinical trial options, therapies or both. Powered by the SmartGenomics platform, PathGroup offers comprehensive disease interrogation through all stages of cancer. The personalized medicine menu includes 62 and 85 gene panels for relapsed or refractory solid tumors and hematomalignancies, whole genome array analysis of greater than 22,000 genes, and disease-specific sequencing at initial diagnosis. With a best-in-class precision oncology suite, PathGroup provides a total lab solution for community-based oncologists from clinical to genomic.

Members of the oncology community have expressed an increased need for advanced testing earlier in the diagnostic-therapeutic continuum. Tennessee Oncology, one of the largest physician-owned oncology practices in the country, Chief Executive Officer Jeffrey F. Patton, MD, added, “When considering the likelihood of recurrence in many cancers, having a baseline of the most commonly altered pathways for each tumor allows us to determine what changes have occurred since initial diagnosis. Utilizing advanced genomic testing early in the cancer care continuum gives Tennessee Oncology physicians the ability to tailor treatments for each patient’s specific cancer.”

About PathGroup

Founded in 1965, PathGroup has evolved into a premier provider of anatomic, clinical and molecular pathology services.   Privately held and physician centric, PathGroup works seamlessly with customers to provide superior diagnostic services – a vital link in the cycle of patient relationships.  PathGroup uses the latest in proprietary and industry standard technology to deliver fast, accurate results.  The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers and most importantly, patients. One Lab; Total Service.  For more information, visit www.pathgroup.com

Cancer Clinics of Excellence Selects PathGroup as a Preferred Laboratory Service Provider

BRENTWOOD, Tenn. (August 5, 2014) – PathGroup, a leading provider of anatomic, clinical and molecular pathology services, and Cancer Clinics of Excellence (CCE), a national network of community-based oncology practices, is pleased to announce a newly formed partnership utilizing PathGroup’s versatile genomic profiling platform, SmartGenomics™, to further identify pharmacotherapeutic targets for patients within the CCE network.

For Full Release, please CLICK HERE

GenoSpace Named Best of Show Winner at Bio-IT World 2014

Thomson Reuters, PathGroup and GenoSpace collaborate to deliver advanced personalized medicine assays and reports to oncologists.

CAMBRIDGE, MA, – (May 8, 2014)GenoSpace today announced that the company was named a Best of Show grand prize winner at the 2014 Bio-IT World Conference and Expo. GenoSpace for Clinical™ was recognized in the Web-Based Services and Software category for its comprehensive suite of offerings supporting genomic medicine.

Click Here to read the full article.

PathGroup Announces Expansion of Its SmartGenomics Offering to Include Profiling of Hematologic Malignancies

BRENTWOOD, Tenn. (March 17, 2014)PathGroup, one of the largest private providers of pathology services in the United States, today announced launch of the SmartGenomics™ Heme Profile, which provides genomic profiling and information for patients that have failed or been unsuccessful on repeated therapy for the group of cancers that include leukemias, lymphomas and myeloproliferative/myelodysplastic diseases.  The newly launched offering is based on collaboration between PathGroup, GenoSpace and the IP & Science business of Thomson Reuters.

The SmartGenomics™ Heme Profile includes Next-Generation DNA Sequencing (NGS) of 77 clinically actionable genes mutated in hematolymphoid cancers and is complemented by Array-based Comparative Genomic Hybridization (aCGH) for whole genome level identification of chromosomal copy number changes and loss of heterozygosity (LOH).  Results provide the treating oncologist with prognostic, predictive, and therapeutic information, as well as available clinical trial options.

Prevalence estimates from the National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) Cancer Statistics Review1, indicate that there are approximately one million individuals in the country that are living with a diagnosis of Hodgkin disease, leukemia, multiple myeloma, or Non-Hodgkin lymphoma, in addition to myeloproliferative/myelodysplastic diseases.  Up to 50% of these diseases ultimately are refractory to treatment.  Furthermore, many of these malignancies are increasing in incidence and pose a significant health care burden.

“When PathGroup committed to providing genomic profiling to community oncologists and researchers, we understood early in the development process that independent interrogation of cancers originating in the bone marrow, blood, and lymphatic system, would be an imperative complement to any exploration of solid tumors,” stated Ben Davis, MD, Chairman, President and CEO of PathGroup.  “As was the case when we released SmartGenomics for solid tumors, we will continue to rely on the exceptional data aggregation and reporting that GenoSpace and Thomson Reuters afford PathGroup in modeling a best-in-class precision oncology offering.”

“The GenoSpace team has been honored to work with PathGroup and is impressed with their approach to developing an integrated personalized medicine offering,” said John Quackenbush, PhD, CEO of GenoSpace. “We are pleased to see PathGroup expand its use of the GenoSpace FullView™ platform to integrate and interpret complex genomic, clinical and demographic information to benefit patients with hematologic malignancies.”

Further, Joseph Donahue, senior vice president, Thomson Reuters Life Sciences commented, “Thomson Reuters is committed to collaborating with innovative organizations like PathGroup and GenoSpace to deliver valuable, new solutions for Life Science clinicians.  The latest phase of our work with these partners, in providing patient-specific genomic intelligence for stratifying cancers, is rooted in the high quality, curated content in Cortellis™, and brings us closer to finding more precise treatments and therapies for oncology patients, regardless of their tumor type or disease.”

1 Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.

About PathGroup

Founded in 1965, PathGroup has evolved into a premier provider of anatomic, clinical and molecular pathology services. Privately held and physician centric, PathGroup works seamlessly with customers to provide superior diagnostic services – a vital link in the cycle of patient relationships.  PathGroup uses the latest in proprietary and industry standard technology to deliver fast, accurate results. The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers and most importantly, patients. One Lab; Total Service. For more information, visit www.pathgroup.com.

About GenoSpace

 At GenoSpace, we are Digital Architects of Genomic Medicine™. GenoSpace is a Cambridge, Massachusetts-based company that has developed robust software systems for securely storing vast amounts of genomic and health data, and providing it in formats specific to its diverse user communities. GenoSpace for Clinical Care facilitates clinically actionable interpretation and report generation for precision medicine. GenoSpace for Research provides dynamic analysis, visualization and collaboration tools. GenoSpace for Patient Communities enables patient-centric exploration and advancement of personalized medicine. Please visit www.GenoSpace.com for more information.

About Thomson Reuters

Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world’s most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.

CONTACTS

Daniel Meyer
GenoSpace, LLC
pr@genospace.com
(617) 520-4182

Laura Gaze
Thomson Reuters
laura.gaze@thomsonreuters.com
(203) 535-6283

 

PathGroup Expands Footprint With Two New Dedicated Laboratories

BRENTWOOD, Tenn. (December 3, 2013) – PathGroup, one of the largest private providers of pathology services in the United States, announced today that it has opened two new state-of-the-art facilities dedicated exclusively to molecular and cytology testing. The new laboratories are adjacent to PathGroup’s current laboratory at 658 Grassmere Park in Nashville, Tenn.

For Full Release, please CLICK HERE

Pathgroup To Deliver New Tools To Community Oncologists For Advancing Personalized Medicine

Brentwood, Tenn.- (September 13, 2013) – PathGroup, one of the largest private providers of pathology services in the United States, announced today that it will begin offering Next-Generation Sequencing (NGS) and Cytogenomic Array (Array-Based Comparative Genomic Hybridization [aCGH]) for genetic profiling of cancer patients in late Q3 of this year. PathGroup’s SmartGenomics™ Profile will provide community-based oncologists with access to tests and data to make more precise, personalized therapeutic recommendations.

For Full Release, please CLICK HERE

 

Cancer Patients to See More Precise Oncology Treatment via Innovative Life Sciences Coalition

Thomson Reuters, PathGroup and GenoSpace collaborate to deliver advanced personalized medicine assays and reports to oncologists

PHILADELPHIA, (August 13, 2013)GenoSpace, PathGroup and the IP & Science business of Thomson Reuters today announced an innovative initiative to develop and deliver a best-in-class personalized medicine service in oncology, the result of which will enable physicians to make more precise therapeutic recommendations for cancer patients.

Click Here to read the full article.

Standard of Care Hits Close to Home – CAP Today

Brentwood, Tenn (May 30, 2013) -Dr. Pranil K. Chandra, Director of Molecular Pathology Services and Interim Medical Director of Clinical Pathology at PathGroup, is featured in the latest addition of CAP Today discussing how he and his molecular pathology team work to maintain gown-level care across multiple cities and states.

Click Here to read the full article.